Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.

NCT00258765 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Poor recruitment \& not feasible to continue

Conditions

Prostate Cancer

Interventions

DRUG: Zoledronic Acid
DRUG: Docetaxel

Sponsor

Novartis Pharmaceuticals